Skip to main content

Table 1 Clinicopathological characteristics of advanced ESCC patients treated with ICI + CT

From: Predicting response to immunotherapy plus chemotherapy in patients with esophageal squamous cell carcinoma using non-invasive Radiomic biomarkers

Characteristics Total Non-Responders Responders P
(n = 64) (n = 32) (n = 32)
Age, year 0.206 †
 <60 37 (57.8%) 16 (50%) 21 (65.6%)  
  ≥ 60 27 (42.2%) 16 (50%) 11 (34.4%)  
Gender, n (%) 1.000 †
 Female 10 (15.6%) 5 (15.6%) 5 (15.6%)  
 Male 54 (84.4%) 27 (84.4%) 27 (84.4%)  
BMI, n (%) 1.000 †
 <18.5 4 (6.3%) 2 (6.3%) 2 (6.3%)  
  ≥ 18.5 and <24 46 (71.9%) 23 (71.9%) 23 (71.9%)  
  ≥ 24 14 (21.9%) 7 (21.9%) 7 (21.9%)  
T stage, n (%) 0.633 §
 T1 3 (4.7%) 1 (3.1%) 2 (6.3%)  
 T2 11 (17.2%) 5 (15.6%) 6 (18.8%)  
 T3 31 (48.4%) 18 (56.3%) 13 (40.6%)  
 T4 19 (29.7%) 8 (25%) 11 (34.4%)  
N stage, n (%) 0.585 †
 N1 18 (28.1%) 10 (31.3%) 8 (25%)  
 N2 24 (37.5%) 10 (31.3%) 14 (43.8%)  
 N3 22 (34.4%) 12 (37.5%) 10 (31.3%)  
 Metastasis, n (%) 19 (29.7%) 13 (40.6%) 6 (18.8%) 0.055 †
 Decreased hemoglobin, n (%) 6 (9.4%) 4 (12.5%) 2 (6.3%) 0.668 §
 Normal albumin, n (%) 64 (100%) 32 (100%) 32 (100%) NA
 Increased leucocyte, n (%) 10 (15.6%) 5 (15.6%) 5 (15.6%) 1.000 †
 C-reactive protein≥10 mg/L, n (%) 31 (48.4%) 13 (40.6%) 18 (56.3%) 0.211 †
 Underlying diseases, n (%) 21 (32.8%) 10 (31.3%) 11 (34.4%) 0.790 †
  1. Abbreviations: ICI + CT-Immune-Checkpoint Inhibitor plus Chemotherapy, BMI-Body Mass Index, NA-Not Applicable. † − Pearson chi-square test, §-Fisher’s Exact Test